Trilostane (Win 24540; Modrastane) 是一种用于治疗库欣综合征的 3 β-羟基类固醇脱氢酶抑制剂。
Cas No. | 13647-35-3 |
别名 | 曲洛司坦; Win 24540 |
化学名 | (1aR,4aR,4bS,6aS,7S,9aS,9bS,11aS)-2,7-dihydroxy-4a,6a-dimethyl-1a,4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11-tetradecahydrocyclopenta[7,8]phenanthro[1,10a-b]oxirene-3-carbonitrile |
Canonical SMILES | N#CC1=C([C@@]2([H])O[C@@]2(C([H])([H])C3([H])[H])[C@@](C1([H])[H])(C([H])([H])[H])[C@]4([H])[C@]3([H])[C@@](C([H])([H])C([H])([H])[C@]5([H])O[H])([H])[C@]5(C([H])([H])[H])C([H])([H])C4([H])[H])O[H] |
分子式 | C20H27NO3 |
分子量 | 329.43 |
溶解度 | ≥ 16.35 mg/mL in DMSO |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Trilostane(Win 24540; Modrastane) is an inhibitor of 3 β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome.IC50 value:Target: 3 β-HSDTrilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase (3-β-HSD or delta 5-delta 4-isomerase), an essential enzyme for the biosynthesis of all classes of hormonal steroids. It has been used in the treatment of Cushing′s syndrome for stopping the production of cortisol, and is currently approved for dogs in the US, but is still a human drug in the UK and other countries. It is being investigated as a possible treatment for both breast cancer and prostate cancer to prevent the synthesis of estrogens and androgens from endogenous precursors. It has also been used to inhibit endogenous production of progesterone in research studies. References: [1]. Helm JR, et al. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane. J Vet Intern Med. 2011 Mar-Apr;25(2):251-60. [2]. Feldman EC, et al. Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs. J Vet Intern Med. 2012 Jul-Aug;26(4):1078-80. |